Ceftazidime is a valuable third-generation bactericidal cephalosporin. Ceftazidime inhibits
the biosynthesis of bacterial cell peptidoglycan, causing inhibition of bacterial growth or cell …

Ceftazidime pharmacokinetics in 28 preterm infants (gestational ages, 25.6 to 31.9 weeks)
were studied on day 3 of life. Patients with suspected septicemia were randomized on day 1 …

The efficacy of ceftazidime in the treatment of neonatal sepsis was studied in 42 low
birthweight premature babies. Forty-nine courses of ceftazidime (25 mg/kg bd, iv or im were …

Doses of 50 mg of ceftazidime per kg were administered intravenously to 29 newborn infants
every 8 or 12 h for 3 to 5 days. Mean peak concentrations in plasma ranged from 102 to 124 …

Ceftazidime pharmacokinetics were studied in 13 preterm newborns requiring antibiotic
treatment, following intramuscular administration of a 50 mg/kg dose in the first 24 hours of …

Ceftazidime, a new parenteral broad spectrum cephalosporin, is stable to most β-
lactamases and has high activity against Pseudomonas species, Providencia, Serratia and …

Fifty neonates and infants with suspected or proven bacterial infection were given 30 mg/kg
of ceftazidime as a single intravenous dose to investigate the pharmacokinetics of …

The pharmacokinetics and safety of ceftazidime (25 mg/kg twice daily intravenously or
intramuscularly) were determined in 41 young, premature neonates who were clinically …

A pharmacokinetic study of ceftazidime was conducted in 1983, together with a clinical
study, on 7 neonates (3 of them premature), 4 infants and 3 children. The antibiotic was …

Ceftazidime, a new cephalosporin antibiotic, was used as monotherapy to treat 75 term
neonates with suspected perinatal bacterial infection. Septicemia was documented in ten …